Marinus Pharmaceuticals Management
Management criteria checks 2/4
Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 5.5 years. total yearly compensation is $3.21M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $64.63K. The average tenure of the management team and the board of directors is 4.3 years and 3.6 years respectively.
Key information
Scott Braunstein
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 20.2% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$149m |
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$3m | US$650k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$3m | US$591k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$4m | US$574k | -US$99m |
| Sep 30 2021 | n/a | n/a | -US$88m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$4m | US$556k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$72m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$2m | US$305k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$210k | n/a | -US$37m |
Compensation vs Market: Scott's total compensation ($USD3.21M) is above average for companies of similar size in the US market ($USD640.92K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
CEO
Scott Braunstein (61 yo)
5.5yrs
Tenure
US$3,214,100
Compensation
Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 5.5yrs | US$3.21m | 0.22% $ 64.6k | |
| COO, CFO & Treasurer | 3.8yrs | US$1.44m | 0.031% $ 9.4k | |
| Chief Medical Officer | 5.3yrs | US$1.37m | 0.031% $ 9.3k | |
| Chief Scientific Officer | no data | no data | no data | |
| Senior VP of Investor Relations | 1.7yrs | no data | no data | |
| Senior VP | 4.7yrs | no data | 0.022% $ 6.6k | |
| Director of Corporate Communications & Investor Relations | 1.7yrs | no data | no data | |
| Chief Regulatory & Quality Assurance Officer | no data | no data | no data | |
| Chief Commercial Officer | 4.3yrs | no data | 0.034% $ 10.2k | |
| Chief Chemistry | no data | no data | no data |
4.3yrs
Average Tenure
61yo
Average Age
Experienced Management: MRNS's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 6.4yrs | US$3.21m | 0.22% $ 64.6k | |
| Lead Independent Director | 16.2yrs | US$202.52k | 0.025% $ 7.6k | |
| Independent Director | 5.2yrs | US$162.52k | 0.016% $ 4.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.4yrs | US$160.02k | 0.011% $ 3.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.1yrs | US$249.21k | no data | |
| Independent Director | 1.8yrs | US$304.81k | 0.0098% $ 2.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | less than a year | no data | no data | |
| Member of the Scientific Advisory Board | less than a year | no data | no data |
3.6yrs
Average Tenure
61yo
Average Age
Experienced Board: MRNS's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 03:40 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marinus Pharmaceuticals, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| François Brisebois | Craig-Hallum Capital Group LLC |
| Douglas Tsao | H.C. Wainwright & Co. |